Selective Estrogen Receptor Modulators
Selective estrogen receptor modulators (SERMs) have been developed to find agents that have as many of the beneficial effects of estrogen as possible but without any of the estrogenic side effects.
Raloxifene is the first SERM that has been shown to decrease the risk of vertebral fractures in women with postmenopausal osteoporosis.
Preliminary data indicate that raloxifene could decrease the risk of breast cancer and cardiovascular events.
KeywordsBreast Cancer Postmenopausal Woman Vertebral Fracture Menopausal Symptom Selective Estrogen Receptor Modulator
Unable to display preview. Download preview PDF.
- Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282: 637–645.CrossRefGoogle Scholar